Stock MDXH MDXHEALTH SA
Add to a list
To use this feature you must be a member
Log inSign up

Ratings MDxHealth SA

Equities

MDXH

BE0974461940

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
2.73 USD -1.44% Intraday chart for MDxHealth SA -5.21% -30.71%
May. 01 MDxHealth SA Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 01 Transcript : MDxHealth SA, Q1 2024 Earnings Call, May 01, 2024

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 61% by 2026.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Over the past four months, analysts' average price target has been revised upwards significantly.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • Low profitability weakens the company.
  • For the last few months, analysts have been revising downwards their earnings forecast.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
MDXHEALTH SA Stock MDxHealth SA
-30.71% 74.5M - -
MODERNA, INC. Stock Moderna, Inc.
+67.53% 63.85B
B-
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.77% 41.83B
B
LONZA GROUP AG Stock Lonza Group AG
+45.66% 40.65B
A
CELLTRION, INC. Stock Celltrion, Inc.
-10.72% 27.12B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.30% 26.52B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.79% 18.69B
B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+4.70% 12.73B
B+
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+24.10% 12.11B
B+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.41% 12.07B
C+
Investor Rating
-
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
  1. Stock Market
  2. Equities
  3. MDXH Stock
  4. Ratings MDxHealth SA